 | Up a level |
Aringer, M; Burkhardt, H; Burmester, G R; Fischer-Betz, R; Fleck, M; Graninger, W; Hiepe, F; Jacobi, A M; Kötter, I; Lakomek, H J; Lorenz, H M; Manger, B; Schett, G; Schmidt, R E; Schneider, M; Schulze-Koops, H; Smolen, J S; Specker, C; Stoll, T; Strangfeld, A; ... (2012). Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus, 21(4), pp. 386-401. London: Sage 10.1177/0961203311426569
Meier, FM; Frommer, KW; Dinser, R; Walker, UA; Czirjak, L; Denton, CP; Allanore, Y; Distler, O; Riemekasten, G; Valentini, G; Müller-Ladner, U; Matucci-Cerinic, M; Guiducci, S; Tyndall, A; Lapadula, G; Iannone, F; Becvar, R; Sierakowsky, S; Kowal-Bielecka, O; Cutolo, M; ... (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the rheumatic diseases, 71(8), pp. 1355-1360. London: BMJ Publishing Group 10.1136/annrheumdis-2011-200742
